Clinical trials: Lymphoepithelioma

Hodgkin Disease, Non Hodgkin Lymphoma

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

• Completed
• Age: All ages
• Phase 1
• Results posted

This protocol is broken up into 2 portions to determine the maximum tolerated dose for treating patients with a type of lymph gland disease.

Conditions

Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma

Trial name

ALCI (NCT00062868)

Testing

LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C)

Where

2 sites in United States

Volunteers

74 people

Sponsor

Baylor College of Medicine